Reaction
Patient Dissatisfaction With Treatment reporting signals
As of the last recalculation, Patient Dissatisfaction With Treatment appears in 1,870 FAERS reports alongside 29 co-occurring drug terms. The strongest observed disproportionality signal is NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE (PRR 550.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Naltrexone Hydrochloride And Bupropion Hydrochloride | 344 | 550.0 | 573.3 |
| Lifitegrast | 39 | 27.1 | 27.2 |
| 0Xygen | 84 | 19.8 | 19.9 |
| Oxygen | 84 | 19.8 | 19.9 |
| Treprostinil | 139 | 13.2 | 13.3 |
| Loratadine Tablet | 56 | 11.9 | 12.0 |
| Amikacin | 18 | 11.8 | 11.9 |
| Fremanezumab-Vfrm | 12 | 11.7 | 11.7 |
| Cariprazine | 9 | 10.8 | 10.8 |
| Levodopa | 11 | 10.2 | 10.2 |
| Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate | 30 | 8.2 | 8.2 |
| Belimumab | 21 | 7.5 | 7.5 |
| Loratadine | 67 | 7.2 | 7.2 |
| Nintedanib | 18 | 6.4 | 6.4 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 6 | 6.4 | 6.4 |
| Botulinum Toxin Type A | 7 | 6.3 | 6.3 |
| Sildenafil | 32 | 6.2 | 6.2 |
| Macitentan | 38 | 6.2 | 6.2 |
| Onabotulinumtoxina | 42 | 6.2 | 6.2 |
| Mepolizumab | 27 | 6.1 | 6.1 |
| Rifaximin | 11 | 5.9 | 5.9 |
| Naproxen Sodium Tablet | 22 | 4.7 | 4.7 |
| Loratadine And Pseudoephedrine Sulfate | 3 | 4.2 | 4.2 |
| Cabotegravir | 3 | 4.1 | 4.1 |
| Dimethyl Fumarate | 40 | 3.7 | 3.7 |
| Bimatoprost | 9 | 3.5 | 3.5 |
| Esketamine Hydrochloride | 5 | 3.1 | 3.1 |
| Patiromer | 3 | 2.4 | 2.4 |
| Adapalene | 3 | 0.2 | 0.2 |